Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer

被引:31
作者
Dasi, F.
Martinez-Rodes, P.
March, J. A.
Santamaria, J.
Martinez-Javaloyas, J. M.
Gil, M.
Alino, S. F.
机构
[1] Univ Valencia, Sch Med, Dept Pharmacol, Valencia 46010, Spain
[2] Univ Valencia, Sch Med, Unidad Cent Invest Med, Valencia 46010, Spain
[3] Univ Valencia, Clin Hosp, Dept Urol, Valencia 46010, Spain
来源
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM IV | 2006年 / 1075卷
关键词
plasma; serum; hTERT; RNA; prostate cancer;
D O I
10.1196/annals.1368.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this study was to evaluate the potential diagnostic value of quantitative analysis of human telomerase reverse transcriptase (hTERT) mRNA in plasma for noninvasive diagnosis of prostate cancer (PCa). Expression levels of hTERT were analyzed by real-time quantitative RT-PCR in 68 patients showing elevated prostate-specific antigen (PSA) levels and a control group of 44 healthy volunteers. Sensitivity and specificity were determined and compared to the corresponding PSA values. Median values for hTERT gene expression in the PCa patients (0.72 ng; range 0.01-12.86) were statistically significantly higher (P < 0.001) than in the control group (0.13 ng; 0.02-0.35). Patients with clinically confirmed prostatitis showed lower plasma hTERT expression than PCa patients (0.29; 0.01-66.07). At a cutoff value of 0.35 sensitivity and specificity for the diagnosis of PCa were 81% and 60%, respectively. We suggest that hTERT mRNA in plasma is a very specific and sensitive method that may aid to differentiate between malignant and nonmalignant prostate tissue and may be a useful marker (in combination with PSA) for early PCa diagnosis.
引用
收藏
页码:204 / 210
页数:7
相关论文
共 14 条
  • [1] Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity
    Botchkina, GI
    Kim, RH
    Botchkina, IL
    Kirshenbaum, A
    Frischer, Z
    Adler, HL
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3243 - 3249
  • [2] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [3] Chen XQ, 2000, CLIN CANCER RES, V6, P3823
  • [4] Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA:: A simple blood test to monitor disease in cancer patients
    Dasí, F
    Lledó, S
    García-Granero, E
    Ripoll, R
    Marugán, M
    Tormo, M
    Garcia-Conde, J
    Aliño, SF
    [J]. LABORATORY INVESTIGATION, 2001, 81 (05) : 767 - 769
  • [5] de Kok JB, 2002, CANCER RES, V62, P2695
  • [6] PROSTATE-CANCER SCREENING IN THE PROSTATE, LUNG, COLORECTAL AND OVARIAN-CANCER SCREENING TRIAL OF THE NATIONAL-CANCER-INSTITUTE
    GOHAGAN, JK
    PROROK, PC
    KRAMER, BS
    CORNETT, JE
    [J]. JOURNAL OF UROLOGY, 1994, 152 (05) : 1905 - 1909
  • [7] Cancer statistics, 2003
    Jemal, A
    Murray, T
    Samuels, A
    Ghafoor, A
    Ward, E
    Thun, MJ
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) : 5 - 26
  • [8] Kopreski MS, 1999, CLIN CANCER RES, V5, P1961
  • [9] Lledo S M, 2004, Colorectal Dis, V6, P236, DOI 10.1111/j.1463-1318.2004.00627.x
  • [10] Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma
    Miura, N
    Maeda, Y
    Kanbe, T
    Yazama, H
    Takeda, Y
    Sato, R
    Tsukamoto, T
    Sato, E
    Marumoto, A
    Harada, T
    Sano, A
    Kishimoto, Y
    Hirooka, Y
    Murawaki, Y
    Hasegawa, J
    Shiota, G
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3205 - 3209